Christopher Lipinski, Ph.D.

Pharmaceutical Consultant

Dr. Lipinski is a world-renowned medicinal chemist best known for his groundbreaking “Rule of Five” which has become a critical filter for drug development programs. An algorithm that helps identify successful drug candidates, this landmark contribution to drug development has influenced the way that the pharmaceutical industry approaches the development of orally active drugs. Drug discovery programs worldwide use the Rule as a filter in high-throughput screening libraries.

Currently, Dr. Lipinski is an independent medicinal chemistry consultant. In 2002 he retired from the highest scientific position in the worldwide Pfizer research organization (Senior Research Fellow) and now serves as a Drug-Like Properties consultant to a variety of profit and non for profit organizations.

At Pfizer, from 1970 to 1990, he supervised medicinal chemistry drug discovery laboratories discovering multiple gastrointestinal and diabetic clinical candidates. In this process he became interested in the design of bioisosteres and in drug physical chemical properties and quantitative structure activity relationships, especially as they related to problems of oral activity. In 1990 he established a highly automated laboratory combining computations and experimental physical property measurements. Experimentally, his laboratory provided experimental solubility measurements on medicinal compounds synthesized at the Pfizer Groton site. Computationally he champions a very pragmatic, chemistry end user oriented, approach to the problem of oral activity improvement.

Dr. Lipinksi is a member of the Medicinal Chemistry section of the American Chemical Society, the American Association of Pharmaceutical Sciences and the Society for Biomolecular Sciences. He serves on the scientific advisory board of Melior Discovery, The KU Leuven University, Dundee University and MRC Technology UK drug discovery efforts. He is a member of the editorial board of the journal of Pharmaceutical Sciences and the highlights advisory board of Nature Reviews Drug Discovery and the advisory boards of several other journals. He is a member of the Medicinal Chemistry “Hall of Fame”, the 2006 recipient of an honorary law degree from the University of Dundee; the Society of Biomolecular Sciences’s winner of the 2006 SBS Achievement Award for Innovation in HTS, the American Chemical Society’s 2005 winner of the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances and the 2004 winner of the Division of Medicinal Chemistry Award of the ACS Division of Medicinal Chemistry. He is an adjunct faculty member in Biochemistry at the University of Massachusetts, Amherst, and has over 235 publications and invited presentations and 17 issued US patents.

He received a B.Sc. degree in chemistry from San Francisco State College in 1965 and a Ph.D. in 1968 in physical organic chemistry from the University of California, Berkeley.

Our People